Pregnancy in hyperprolactinemic women.
Pregnancy achieved in women who receive treatment to correct the secretory dysfunction of nontumoral HPRL or microprolactinomas requires close prenatal care, but generally its course does not vary from normal. When a macroprolactinoma is present, consequences of pregnancy are insignificant, provided the tumor has been previously treated or bromocriptine is given continuously during the pregnancy. On those rare occasions when symptoms of tumor growth appear during pregnancy, bromocriptine and dexamethasone effectively control such manifestations. Breast-feeding of the infant can be allowed, and a second pregnancy within a short term is not contraindicated. When a new pregnancy is not desired, nonhormonal contraceptive methods are advised. Patients with nontumoral HPRL and microadenomas require periodic checkups. Macroadenomas may be surgically excised, but longterm bromocriptine treatment also achieves good results and is highly recommended.
D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism*; D001971:Bromocriptine / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008711:Metergoline / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011181:Postnatal Care; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000378:metabolism*; D011295:Prenatal Care; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D008711:Metergoline; D002996:Clomiphene; D001971:Bromocriptine; D011388:Prolactin